Chronic infection with hepatitis C virus (HCV) affects approximately 130–170 million individuals worldwide. It is associated with the development of liver failure and hepatocellular carcinoma and is the leading indication for liver transplantation in developed countries. One of Australia's leading researchers in this area is Professor Alex J Thompson. Alexander Thompson MBBS, FRACP, PhD, is the director of gastroenterology at the Department of Gastroenterology, St Vincent's Hospital in Melbourne.

Alex and his colleagues, through their research sought to develop simple clinical tools that could be used in clinical practice to guide treatment decisions by accurately predicting the likelihood of an individual achieving a sustained virological response (SVR) with a variety of therapies with the drugs Boceprevir, Plus Peginterferon Alfa and Ribavirin. In summary, they developed nomograms for predicting responses to Boceprevir therapy. The nomograms are suitable for point-of-care use to inform individual patient and physician decision-making about the potential duration and success from such treatment.

Revium were asked to bring the SVR nomogram to the internet as a simple treatment calculator.

Goals and Challenges

  • The tool was to allow clinical practitioners to input the individual data, providing field validation and the reference to the research.
  • The calculator was required to be used on small screen devices (smartphone, tablet), as well as to be available for users in a non-JavaScript environment.
  • The team at Revium worked closely with Professor Alex Thompson to develop a test engine for the calculator as a precursor for the online solution.


The completed solution provided the SVR Calculator website as a standalone web application, that can be used in multiple browsers and operating environments. It is written for both a client-side JavaScript ethos and a server-side C#. The site is responsive to any screen width and has the function for the page to be printed and saved as a PDF page.

Note - this site is no longer active.

Newsletter sign up

Every couple of months we send out an update on what's been happening around our office and the web. Sign up and see what you think. And of course, we never spam.